You are here

amyloidosis

Bridgebio sets its heart on besting Pfizer

EP Vantage

Fri, 12/3/21 - 10:31 am

transthyretin amyloid cardiomyopathy

Attralus Eyes Further Work on Therapeutic Candidates with New Funding

BioSpace

Mon, 09/14/20 - 11:41 pm

EU Advisory Group Backs Orphan Drug Designation for Alnylam's ALN-TTRsc02 for ATTR Amyloidosis

Mon, 04/23/18 - 09:37 am

Alnylam outshines Ionis with RNAi drug

BioPharma Dive

Sat, 11/4/17 - 08:40 am

Ionis Pharmaceuticals

Alnylam Reports Positive Phase II Data for Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR), and Initiates Phase III Trial

Yahoo/BusinessWire

Sun, 11/10/13 - 01:08 pm

TTR-mediated amyloidosis

Alnylam Reports Positive Phase II Data for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)

Yahoo/BusinessWire

Sun, 06/30/13 - 10:42 am

TTR-mediated amyloidosis

Millennium starts Phase 3 trial for amyloidosis

Mass High Tech, MA

Sat, 10/20/12 - 11:46 am

Alnylam Pushes Forward In Amyloidosis After Pfizer Setback

Seeking Alpha

Tue, 07/17/12 - 11:08 am

Alnylam initiates Phase II study of ALN-TTR02

Pharmaceutical Business Review

Sat, 06/9/12 - 04:42 pm